Clinical trials: Pancreatic Adenocarcinoma
Pancreatic Neoplasms, Solid Tumors
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms
- Trial name
- NCT05512377
- Testing
- Brigimadlin
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study of INCA 0186 in Subjects With Advanced Solid Tumors
This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when…
- Conditions
- Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
- Trial name
- NCT04989387
- Testing
- INCA00186, Retifanlimab, INCB106385
- Where
- 32 sites in United States, Austria and 4 more
- Volunteers
- 57 people
- Sponsor
- Incyte Corporation
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00544193
- Testing
- gemcitabine hydrochloride, polymerase chain reaction, immunohistochemistry staining method
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Ovarian Cancer, Lung Adenocarcinoma
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
The project aims to perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed pancreatic cancer, ovarian cancer, lung adenocarcinoma and other malignant tumors with high MSLN expression…
- Conditions
- Ovarian Cancer, Lung Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT06843629
- Testing
- Specific positron imaging agents targeting MSLN
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colorectal Cancer, Depression
Studying Pain and Symptom Distress in Patients With Advanced Colon Cancer, Rectal Cancer, Pancreatic Cancer, or Liver Cancer
RATIONALE: Studying a patient's understanding of his or her illness, pain, symptoms, and quality-of-life may help the study of advanced cancer and may help patients live more comfortably.
- Conditions
- Colorectal Cancer, Depression, Fatigue, Liver Cancer
- Trial name
- NCT00950144
- Testing
- medical chart review, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- City of Hope Medical Center
Pancreatic Ductal Adenocarcinoma (PDAC)
HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
To evaluate the safety and efficacy of HRS-4642 combined with Nimotuzumab in patients with recurrent or metastatic pancreatic ductal adenocarcinoma.
- Trial name
- NCT06773130
- Testing
- HRS-4642, Nimotuzumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Pancreatic Cancer
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290693
- Testing
- Capecitabine, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Miami
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer
The purpose of this study is to assess the safety, feasibility, and recommended dose of navlimetostat (BMS-986504) combined with mFOLFIRINOX before and after surgery in patients with localized pancreatic cancer with MTAP deletion.
- Trial name
- M-POP (NCT07905131)
- Testing
- Navlimetostat, mFOLFIRINOX Treatment Regimen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Daniel Nussbaum, M.D.
Pancreas Adenocarcinoma, Cholangiocarcinoma
FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1
Pancreas as well as Cholangiocarcinoma have a dismal prognosis at time of diagnosis, due to late onset of clinical symptoms, patients present with advance disease.
- Trial name
- FLUOPANC (NCT05518071)
- Testing
- CRGD-ZW800-1, Intraoperative near-infrared fluorescence imaging
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Leiden University Medical Center
ePRO, Symptom Monitoring
Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study
To learn if routine symptom monitoring using questionnaires during chemotherapy and/or radiation therapy in patients with PDAC improves patient health-related quality of life and experience with care.
- Conditions
- ePRO, Symptom Monitoring, Neoadjuvant Therapy, Pancreatic Adenocarcinoma
- Trial name
- NCT07829471
- Testing
- Standard of Care
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreas Cancer, Pancreatic Carcinoma
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
- Conditions
- Pancreas Cancer, Pancreatic Carcinoma, Pancreas Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- FORTIFIDE (NCT06592664)
- Testing
- certepetide, nab-paclitaxel, gemcitabine
- Sponsor
- Lisata Therapeutics, Inc.
Pancreatic Cancer
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
- Trial name
- NCT06941857
- Testing
- Oxaliplatin, Irinotecan, Folinic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Neoplasms
Sarcopenia is an Independent Prognostic Factor for Overall Survival in Patients With Pancreatic Adenocarcinoma
The primary objective of this study was to validate Total Psoas Area (TPA) measurement as an independent prognostic factor of overall survival in patients with pancreatic adenocarcinoma.
- Trial name
- NCT02977702
- Volunteers
- 114 people
- Sponsor
- Institut de Cancérologie de Lorraine
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma (PDAC)
"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational Study
To assess whether EUS (Endoscopic Ultrasound) can serve as a valuable diagnostic tool for identifying PDAC at an early stage in individuals who have recently been diagnosed with diabetes.
- Trial name
- NCT06044064
- Testing
- A blood sample for CA 19-9 (cancer detection test)
- Volunteers
- 100 people
- Sponsor
- Asian Institute of Gastroenterology, India
Pancreatic Cancer
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
The purpose of this study is to estimate safety of GVAX Pancreas Vaccine (GVAX) with immune modulating doses of cyclophosphamide (Cy) followed by SBRT and FOLFIRINOX chemotherapy in pancreatic cancer patients after surgery.
- Trial name
- NCT01595321
- Testing
- Cyclophosphamide, GVAX Pancreas Vaccine, Stereotactic Body Radiation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study
Malignant obstructive jaundice is a common complication of advanced stage cholangiocarcinoma, gallbladder cancer, and pancreatic cancer.
- Trial name
- NCT02646514
- Testing
- Radiofrequency ablation with stenting, stenting
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Pancreatic Cancer
Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas
This study is performed to confirm whether resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy could improve survival and relieve pain of pancreatic cancer patients.
- Trial name
- NCT02514928
- Testing
- resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy, standard pancreatoduodenectomy
- Where
- China
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Fudan University
Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
An open-label dose escalating phase Ib study of SCO-101 in combination with gemcitabine and nab-paclitaxel. The primary objectives are to establish the safety profile and the MTD of SCO-101 when combined with gemcitabine and…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Inoperable Disease, Localized Pancreatic Adenocarcinoma
- Trial name
- PANTAX-Ib (NCT04652206)
- Testing
- SCO-101, Gemcitabine, Nab paclitaxel
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 18 people
- Sponsor
- Scandion Oncology A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.